Abstract
The National Cancer Institute (NCI), in a continuing effort to discover novel anticancer leads, has screened more than 350,000 compounds. Thus, extensive chemical and biological database files have become available. The recent establishment of the chemistry-biology computer interlink offers the opportunity to undertake carefully planned structure-activity studies. Although a selective acquisition approach in the screening program is now adopted by the NCI [1] promising antitumor leads still have to be developed from the screening of large numbers of compounds in various tumor systems. These novel leads can then be optimized through both structure-activity analysis of the total NCI file and analog synthesis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
